Vijaya Diagnostic Centre

VIJAYA closed at ₹1470.8 on 2026-11-06, trading near the upper end of its 20-day (+79.9%) and 52-week (+83.5%) ranges. The daily technical setup is mixed: while price remains above all major moving averages (EMA/SMA 20/50/200), it sits below the Supertrend indicator, which signals a bearish bias. Daily trend strength is weak (ADX 14.45), suggesting a lack of conviction despite recent positive returns (+2.3% in one day, +5.9% over ten days). A Bullish Engulfing Reversal pattern formed today, potentially signaling a short-term bounce after an extreme volume-driven downward anomaly on 2026-11-04. However, monthly momentum remains constructive with a bullish Supertrend and developing trend strength (ADX 21.07). Risk is elevated, with annualized volatility at 40.1% and a current drawdown of -6.4%. Immediate resistance lies at ₹1490.3 (+1.33%), while support is found at ₹1464.0 (-0.46%).

Vijaya Diagnostic Centre reported strong financial performance for the second quarter ended October 2026, with net profit rising 37.4% year-on-year to ₹59.5 crore. This growth was underpinned by a 26.7% increase in revenue and significant margin expansion, as EBITDA margins improved by 350 basis points to reach 44.1%. The company attributed these results to higher test volumes and robust performance in its core markets. Beyond domestic operations, Vijaya announced its strategic entry into the North-East region through the acquisition of Arya Wellness Centre in Guwahati.

Despite the positive earnings report, the market reacted negatively on November 4, 2026, with Vijaya’s shares falling 3%, contrasting with a 6% rise in peer Global Health. This divergence suggests that while the fundamental metrics were strong, investor sentiment or specific details within the Q2 results may have triggered a sell-off, highlighting the disconnect between operational growth and short-term price action.

Vijaya Diagnostic Centre Limited reported unaudited financial results for Q2 and H1 FY2026–27, highlighting strong top-line growth and profitability expansion. Consolidated revenue from operations rose 26.7% year-on-year to ₹2,553.9 million in Q2, with profit after tax increasing 37.4% to ₹594.7 million. For the half-year, revenue grew 24.8% to ₹4,863.7 million, and PAT climbed 37.5% to ₹1,125.7 million. Alongside these figures, the company announced a strategic acquisition via a Business Transfer Agreement to purchase Arya Wellness Centre in Guwahati, Assam, marking its entry into the North-East region. Governance updates include the appointment of Mr. Rahul Jain as Company Secretary and Compliance Officer effective November 03, 2026. The Board also approved the release of investor presentations and audio recordings of earnings calls to ensure transparency.

Vijaya Diagnostic Centre demonstrates a robust expansion trajectory, with total assets growing from ₹1,391 crore in September 2025 to ₹1,733 crore by September 2026. This growth is underpinned by strong operational momentum; Q2 FY2026-27 revenue reached ₹255 crore, up sequentially from ₹231 crore in Q1, while Profit Before Tax rose to ₹79.4 crore from ₹70.9 crore. Earnings quality remains high, evidenced by a Cash Flow from Operations/EBITDA ratio consistently above 96% over the last three years and a negative Cash Conversion Cycle (–117 days as of Mar 2026), indicating efficient working capital management.

Financial health is supported by rising equity (₹1,057 crore) and stable return metrics, including a 21% ROCE. However, borrowing has increased significantly, rising from ₹259 crore in Mar 2024 to ₹423 crore in Mar 2026, coinciding with higher finance costs (₹11.4 crore in Q2 FY26-27). Shareholding patterns show a notable shift: DIIs increased their stake to 32.49% in Sep 2026, while FIIs reduced theirs to 10.67%. The key checkpoint is monitoring whether the expanding asset base translates into sustained operating leverage as debt levels continue to rise.

Vijaya Diagnostic Centre presents a conditional upside case anchored by robust operational momentum and multi-timeframe technical alignment, despite recent short-term price weakness. In the second quarter ended November 2026, the company delivered a 37.4% year-on-year increase in net profit to ₹59.5 crore, driven by a 26.7% revenue rise and significant margin expansion. EBITDA margins improved by 350 basis points to 44.1%, reflecting strong performance in core markets and higher test volumes. This fundamental strength is complemented by strategic geographic expansion through the acquisition of Arya Wellness Centre in Guwahati, signaling entry into the North-East region.

Technically, while the daily trend is bearish with the stock down 3% post-earnings, the weekly and monthly trends remain bullish. The weekly Supertrend is positive, and the stock has maintained strong relative performance over longer horizons, including a +44.5% return over the past year and +41.1% year-to-date. Key resistance levels at ₹1,490.3 and ₹1,501.0 represent immediate hurdles; a sustained move above these levels could validate the broader bullish structure. Investors should monitor whether the company can translate its margin efficiency and regional expansion into continued earnings growth to overcome near-term volatility.

Vijaya Diagnostic Centre faces near-term technical headwinds despite strong underlying profitability. Following its Q2 earnings release, which reported a 37.4% year-on-year profit increase to ₹59.5 crore, the stock price fell 3%, indicating that market participants may be pricing in caution or taking profits after significant prior gains. The daily technical setup is currently bearish, with the SuperTrend indicator signaling downside pressure and the 50-day simple moving average (SMA) slope at -4.42, suggesting a short-term trend reversal. Price action has pulled back from recent highs, with the stock trading at ₹1,470.8 against immediate resistance at ₹1,490.3 (1.33% above). While the monthly trend remains bullish, the divergence between long-term momentum and short-term weakness highlights a period of consolidation or correction. Investors should monitor whether the stock holds above the pivot support level at ₹1,438.2; a break below this level could expose further downside toward the low support at ₹1,411.9.